36 studies found for:    MLN9708
Show Display Options
Rank Status Study
1 Recruiting MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies
Condition: Advanced Cancers
Interventions: Drug: MLN9708;   Drug: Vorinostat
Phase: Phase 1
Sponsor/Collaborators: M.D. Anderson Cancer Center;   Millennium Pharmaceuticals, Inc.
Study Start: June 2014
Primary Completion: June 2021
2 Not yet recruiting Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib Citrate in Lupus Nephritis
Condition: Lupus Nephritis
Interventions: Drug: Ixazomib Citrate;   Drug: Placebo
Phase: Phase 1
Sponsor: Takeda
Study Start: June 2014
Primary Completion: December 2015
3 Recruiting Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: MLN9708
Phase: Phase 2
Sponsor/Collaborators: SCRI Development Innovations, LLC;   Millennium Pharmaceuticals, Inc.
Study Start: August 2014
Primary Completion: June 2017
4 Recruiting MLN 9708 With Lenalidomide as Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma Patients
Condition: Myeloma
Interventions: Drug: Lenalidomide;   Drug: MLN9708;   Radiation: Questionnaires
Phase: Phase 2
Sponsor/Collaborators: M.D. Anderson Cancer Center;   Millennium Pharmaceuticals, Inc.
Study Start: December 2012
Primary Completion: December 2017
5 Active, not recruiting Study of Oral MLN9708 in Adult Patients With Relapsed or Refractory Light Chain Amyloidosis
Condition: Light-Chain Amyloidosis
Intervention: Drug: MLN9708
Phase: Phase 1
Sponsor: Millennium Pharmaceuticals, Inc.
Study Start: May 2011
Primary Completion: December 2013
6 Not yet recruiting Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults
Conditions: Acute Lymphoblastic Leukemia;   Lymphoblastic Lymphoma;   B-cell Adult Acute Lymphoblastic Leukemia;   T-cell Adult Acute Lymphoblastic Leukemia
Interventions: Drug: MLN 9708;   Drug: Vincristine;   Drug: Cytarabine;   Drug: Doxorubicin;   Drug: Mercaptopurine;   Drug: Cyclophosphamide;   Drug: Methotrexate
Phase: Phase 1
Sponsor/Collaborators: Massachusetts General Hospital;   Millennium Pharmaceuticals, Inc.
Study Start: August 2014
Primary Completion: October 2017
7 Not yet recruiting Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06)
Condition: Newly Diagnosed Multiple Myeloma
Interventions: Drug: MLN9708;   Drug: Lenalidomide;   Drug: Dexamethasone
Phase: Phase 2
Sponsor: Nantes University Hospital
Study Start: October 2013
Primary Completion: January 2019
8 Not yet recruiting A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant
Conditions: Multiple Myeloma;   Autologous Stem Cell Transplant
Interventions: Drug: Ixazomib Citrate;   Drug: Placebo
Phase: Phase 3
Sponsor: Millennium Pharmaceuticals, Inc.
Study Start: July 2014
Primary Completion: February 2018
9 Recruiting MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma
Conditions: Multiple Myeloma;   Kahler Disease;   Plasma-Cell Myeloma;   Myelomatosis
Interventions: Drug: Panobinostat;   Drug: Dexamethasone;   Drug: MLN9708
Phase: Phase 1
Sponsor: Case Comprehensive Cancer Center
Study Start: May 2014
Primary Completion: July 2015
10 Recruiting Phase I Study of (Modified VXLD) Plus MLN9708 in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma
Conditions: Relapsed or Refractory Acute Lymphoblastic Leukemia;   Relapsed or Refractory Lymphoma
Interventions: Drug: MLN9708;   Drug: Vincristine;   Drug: Doxorubicin;   Drug: PEG asparaginase;   Drug: Dexamethasone
Phase: Phase 1
Sponsor/Collaborators: Ehab L Atallah;   Medical College of Wisconsin
Study Start: October 2013
Primary Completion: December 2017
11 Not yet recruiting Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas
Condition: Lymphoma, T-Cell
Intervention: Drug: MLN9708
Phase: Phase 2
Sponsor: University of Michigan Cancer Center
Study Start: August 2014
Primary Completion: August 2018
12 Not yet recruiting Nonmyeloablative Haploidentical Transplant Followed by MLN9708
Conditions: Acute Leukemia;   Chronic Leukemia;   Myelodysplastic Syndrome;   Lymphomas;   Multiple Myeloma
Intervention: Drug: MLN9708
Phase: Phase 2
Sponsor/Collaborators: Northside Hospital, Inc.;   Millennium Pharmaceuticals, Inc.
Study Start: June 2014
Primary Completion: July 2016
13 Withdrawn MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: MLN9708;   Drug: Dexamethasone
Phase: Phase 2
Sponsor/Collaborators: National Cancer Institute (NCI);   National Institutes of Health Clinical Center (CC)
Study Start: July 2012
Primary Completion: March 2014
14 Not yet recruiting Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Treating Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Recurrent Adult Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
Interventions: Drug: ixazomib;   Drug: mitoxantrone hydrochloride;   Drug: etoposide;   Drug: cytarabine
Phase: Phase 1
Sponsor/Collaborators: Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Study Start: May 2014
Primary Completion: November 2017
15 Recruiting Ixazomib in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib
Condition: Refractory Multiple Myeloma
Interventions: Drug: ixazomib;   Drug: dexamethasone
Phase: Phase 2
Sponsor/Collaborators: Mayo Clinic;   National Cancer Institute (NCI)
Study Start: January 2012
Primary Completion: December 2014
16 Recruiting Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Condition: Refractory Multiple Myeloma
Interventions: Drug: ixazomib;   Drug: dexamethasone;   Drug: pomalidomide;   Other: laboratory biomarker analysis
Phases: Phase 1 / Phase 2
Sponsor/Collaborators: City of Hope Medical Center;   National Cancer Institute (NCI)
Study Start: June 2014
Primary Completion: June 2017
17 Recruiting Cyclophosphamide, Ixazomib, and Dexamethasone in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma
Conditions: Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: ixazomib;   Drug: cyclophosphamide;   Drug: dexamethasone;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Other: quality-of-life assessment
Phases: Phase 1 / Phase 2
Sponsor/Collaborators: Mayo Clinic;   National Cancer Institute (NCI)
Study Start: August 2013
Primary Completion: December 2015
18 Recruiting Ixazomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: ixazomib;   Other: laboratory biomarker analysis
Phase: Phase 2
Sponsor/Collaborators: Bruno C. Medeiros;   National Cancer Institute (NCI);   Stanford University
Study Start: March 2014
Primary Completion: March 2016
19 Recruiting Phase 2 Study of Oral IXAZOMIB in Adult Patients With Relapsed and/or Refractory Follicular Lymphoma
Condition: Follicular Lymphoma
Intervention: Drug: IXAZOMIB
Phase: Phase 2
Sponsor: Millennium Pharmaceuticals, Inc.
Study Start: November 2013
Primary Completion: June 2016
20 Recruiting Phase 1 Pharmacokinetic Study of Oral IXAZOMIB Plus Lenalidomide and Dexamethasone in Adult Asian Patients With Relapsed and/or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: IXAZOMIB
Phase: Phase 1
Sponsor: Millennium Pharmaceuticals, Inc.
Study Start: December 2012
Primary Completion: June 2015

Previous Page Studies Shown (1-20) Next Page (21-36) Show next page of results
Indicates status has not been verified in more than two years